Likewise, SR-B2/CD36+ human oral carcinoma cells initiate metastasis in an SR-B2/CD36-dependent manner, and SR-B2/CD36 antibody therapy inhibited metastasis in preclinical models [54]. Here, MED20 is linked to lip and oral cavity carcinoma.